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Introduction {#sec005}
============

Treatment of chronic hepatitis C (HCV) infection in the United States has been revolutionized with the development of novel direct-acting antiviral (DAA) therapies. DAA therapy has demonstrated better tolerability, adherence, as well as rates of sustained virologic response (SVR) and cure compared to antecedent interferon (IFN)-based therapies \[[@pone.0135645.ref001]--[@pone.0135645.ref004]\]. This advance has expanded the population of individuals with HCV infection who are potentially treatable. Owing to its efficacy, the American Association for the Study of Liver Disease (AASLD) and the Infectious Disease Society of America (IDSA) have modified their recommendations to include the combination of sofosbuvir and ledipasvir (SOF/LED) as first-line therapy for HCV genotype-1 infection, the most prevalent strain seen in the United States \[[@pone.0135645.ref003], [@pone.0135645.ref005]--[@pone.0135645.ref008]\].

However, care provision requires successful completion of numerous steps along a care continuum \[[@pone.0135645.ref009]\]. It has been recently estimated that only 16% of chronic HCV-infected individuals are prescribed antiviral treatment and only 9% achieve SVR \[[@pone.0135645.ref010]\] although this represents data from the interferon era and precedes the advent of all-oral anti-HCV regimens. The concept of a care cascade (diagnosis, linkage to care, retention in care, prescription of antiretroviral therapy, and viral suppression) has been utilized as a means for identifying care gaps and setting goals in patients with human immunodeficiency virus (HIV) infection, HCV-HIV co-infection, and recently for HCV mono-infected individuals as well \[[@pone.0135645.ref011]--[@pone.0135645.ref015]\]. Recently, barriers to completion of therapy have been reported which include but are not limited to diagnosis, knowledge of treatment options, completion of pre-treatment paperwork, lack of insurance coverage, medical eligibility, lack of program infrastructure for vulnerable populations, and medication costs \[[@pone.0135645.ref016]--[@pone.0135645.ref020]\]. To this effect, some interventions to improve access have also been proposed, such as provision for self-referral and shortened treatment duration \[[@pone.0135645.ref021], [@pone.0135645.ref022]\].

Among the steps in HCV treatment provision, pre-authorization (also known as prior authorization, prior approval, or pre-certification) is the process by which a health insurance provider determines that specific treatment is medically necessary, and which allows for insurance coverage of treatment cost. It is currently known that DAA therapy is expensive with prices ranging from \$63,000 to \$300,000 per treatment course. The wholesale cost of a 12-week treatment course of SOF/LED is \$94,500, amounting to \$1,125 per pill \[[@pone.0135645.ref023]\]. As this results in prohibitive cost and limited availability, pre-authorization often requires that patients have advanced fibrosis (grade F3 or beyond) or cirrhosis to be given treatment priority \[[@pone.0135645.ref024]\].

Currently there are limited data on rate and timing of insurance pre-authorization after SOF/LED prescriptions are written. In this study, we aim to perform a retrospective observational study reporting real-life data of drug approval rates in a cohort of patients with HCV infection who received prescription for SOF/LED treatment over a 3-month period. We also aim to determine factors associated with pre-authorization approval, time to pre-authorization decision, and time to pre-authorization approval. We hypothesize that the majority of patients for whom a pre-authorization request is filed will ultimately receive approval, and that insurance pre-authorization will be within the recommended guidelines for treatment for those with the highest need (i.e. advanced liver disease). However, we also hypothesize that there will be a proportion of patients who are ultimately not approved, as well as some who are approved only after appeal.

Materials and Methods {#sec006}
=====================

Study Subjects {#sec007}
--------------

As part of the SOF/LED acquisition process, all patients had pre-authorization requests sent to their insurance coverage providers. We reviewed the medical charts of all patients at Yale Liver Center who had an insurance pre-authorization request for SOF/LED filed between October 11, 2014 and December 31, 2014. Patients were then excluded if they received a prescription for HCV treatment other than combination SOF/LED.

Outcomes {#sec008}
--------

For each patient, we recorded the insurance provider of pre-authorization request. Those without Medicare or Medicaid insurance carriers were categorized as having private insurance coverage. If a patient was listed as having both Medicaid/Medicare and another insurance provider, they were considered to have a private insurance provider. We recorded approval, denial, or pending status of pre-authorization initial request and appeal as of March 1^st,^ 2015. If an individual was denied treatment and appeal was sought, date of appeal request and date of appeal decision were recorded.

Covariates {#sec009}
----------

Patient characteristics included age, race, body mass index, co-morbid hypertension, psychiatric illness, diabetes, renal disease, hepatitis B or HIV co-infection, and baseline biochemical markers (total bilirubin, serum creatinine, and serum international normalized ratio, INR). We recorded HCV viral characteristics, including genotype, viral load, IL28B gene variant and prior treatment regimens. Severity of HCV infection was determined by progression of hepatic fibrosis. Those with METAVIR stage 4 fibrosis on liver biopsy, clinical hepatic decompensation, or imaging findings suggesting cirrhosis with portal hypertension were classified as having cirrhosis. Advanced fibrosis included those with cirrhosis and included individuals with grade 3 fibrosis on liver biopsy, advanced fibrosis by tissue elastography, and/or an elevated FIB-4 score (\>3.25) \[[@pone.0135645.ref025]\]. In patients with cirrhosis, Child-Pugh class and MELD scores were recorded using laboratory testing closest to the pre-authorization filing date. A subset of patients received their pre-authorization request through their transplant clinic provider. It was noted for those whom this was the case.

Statistical Analysis {#sec010}
--------------------

T-testing was used to compare continuous variables and chi-square testing was used for categorical variables. Univariate and multivariate analyses were performed using linear and logistic regression modeling with forward selection logistic regression to identify significant predictors of pre-authorization approval and times-to-decision or approval. All data were analyzed using SAS 9.4 statistical software (Cary, NC). Full dataset with SAS code used for this analysis is available at [S1 Appendix](#pone.0135645.s001){ref-type="supplementary-material"}.

Ethics Statement {#sec011}
----------------

We obtained approval for conduct of this study by our institutional review board.

Results {#sec012}
=======

A total of 174 patients with chronic HCV infection seen at the Yale Liver Center were prescribed antiviral therapy between October 11^th^ and December 31^st^ 2014, of whom 129 were prescribed SOF/LED. Tables [1](#pone.0135645.t001){ref-type="table"}--[3](#pone.0135645.t003){ref-type="table"} summarize demographic characteristics of this patient population. The mean age was 57.0 ± 9.9 years with 61.2% being males. 60.5% of the population had cirrhosis. [Table 4](#pone.0135645.t004){ref-type="table"} summarizes the outcomes of pre-authorization. Of the 128 for whom pre-authorization status was determined, 100 (77.5%) received initial approval for pre-authorization. 117 (91.4%) of 129 received approval including those who required appeal. Initially, 19 patients (14.7%) required appeal and ultimately 6 (4.7%) were denied. As of March 1^st^, 2015, the pre-authorization status of 5 (3.9%) are pending and 1 (0.0%) is unknown. The average time to final decision (approval or denial) was 26.1 ± 25.2 days, and in those approved the average time to decision was 22.9 ± 21.2 days.

10.1371/journal.pone.0135645.t001

###### Baseline demographic information for patients prescribed SOF/LED from Yale non-transplant hepatology and transplant hepatology clinics from October 1, 2014 to December 30, 2014 (n = 129).

![](pone.0135645.t001){#pone.0135645.t001g}

  Characteristic                    Value                                  
  --------------------------------- -------------------------------------- ------------
                                    Age in years, mean ± SD                57.0 ± 9.9
  Gender, n (%)                     Male                                   79 (61.2)
  Female                            50 (38.8)                              
  Race, n (%)                       White                                  88 (68.2)
  Black                             25 (19.4)                              
  Asian                             4 (3.1)                                
  Other                             11 (8.5)                               
  Unknown                           1 (0.8)                                
  Ethnicity, n (%)                  Non-Hispanic                           106 (82.2)
  Hispanic                          21 (16.3%)                             
  Patient refused/Unk               2 (1.6%)                               
  Medical insurance, n (%)          Private                                63 (49.2)
  Public                            64 (50.0)                              
  Unknown / None                    1 (0.8)                                
  Smoking History, n (%)            Non-smoker                             29 (22.5)
  Prior smoker                      54 (41.9)                              
  Active smoker                     39 (30.2)                              
  Unknown                           7 (5.4%)                               
  Alcohol use history, n (%)        Never                                  36 (27.9)
  Occasional                        29 (22.5)                              
  Prior abuse                       42 (32.6%)                             
  Unknown                           22 (17.1%)                             
  Illicit drug use history, n (%)   Never                                  37 (28.7)
  Prior use                         68 (52.7)                              
  Active use                        6 (4.7)                                
  Unknown                           18 (14.0)                              
                                    Body mass index, mean ± SD             29.0 ± 6.4
                                    Diabetes mellitus, n (%)               31 (24.0)
                                    Hypertension, n (%)                    58 (45.0)
                                    Psychiatric history, n (%)             50 (38.8)
                                    HBV, n (%)                             0 (0)
                                    HIV, n (%)                             3 (2.3)
  GFR, no (%)                       \>60                                   115 (89.2)
  ≤60                               14 (10.9)                              
                                    Followed in transplant clinic, n (%)   34 (26.4)

10.1371/journal.pone.0135645.t002

###### Hepatitis C virus characteristics and disease severity.
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  Characteristic              Value                                  
  --------------------------- -------------------------------------- -----------------------
                              Mean viral load, mean ± SD             2,960,146 ± 4,226,850
                              Log10 (mean viral load)                6.47
  Genotype, n (%)             1A                                     96 (74.4)
  1B                          17 (13.2)                              
  1 subtype unspecified       12 (9.3)                               
  Non-GT1                     2 (1.6)                                
  Unknown                     2 (1.6)                                
  IL28B polymorphism, n (%)   CC                                     21 (16.3)
  CT                          44 (24.1)                              
  TT                          19 (14.7)                              
  Unknown                     45 (34.9)                              
                              Prior HCV treatment, n (%)             57 (44.2)
                              Multiple prior HCV treatments, n (%)   22 (17.1)
                              Presence of advanced fibrosis, n (%)   89 (69.0)
                              Presence of cirrhosis, n (%)           78 (60.5)

10.1371/journal.pone.0135645.t003

###### Baseline characteristics of patients with cirrhosis (n = 78).
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  Characteristic             Value                                         
  -------------------------- --------------------------------------------- -----------
                             MELD score, mean ± SD                         8.2 ± 2.6
  Child-Pugh class, n (%)    A                                             58 (74.4)
  B                          20 (25.6)                                     
                             Presence of decompensated cirrhosis, n (%)    26 (20.2)
                             Presence of ascites, n (%)                    17 (21.8)
                             Presence of encephalopathy, n (%)             18 (23.1)
                             Presence of prior variceal bleed, n (%)       11 (14.1)
                             Presence of jaundice, n (%)                   3 (3.9)
                             Presence of hepatocellular carcinoma, n (%)   18 (23.1)
  Transplant status, n (%)   Not indicated                                 46 (59.0)
  Not eligible               6 (7.7)                                       
  Under evaluation           10 (12.8)                                     
  Listed                     9 (11.5)                                      
  Post-transplant            7 (9.0)                                       

10.1371/journal.pone.0135645.t004

###### Pre-authorization outcomes for patients prescribed SOF/LED between October 11^th^-Dec 31^st^, 2014 (as of March 1^st^ 2015).
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  Characteristic                              Value                                            
  ------------------------------------------- ------------------------------------------------ -------------------
                                              Total for whom outcomes data available, n        129
  Final pre-authorization decision, n (%)     Approval                                         117 (91.4)
  Denial                                      6 (4.7)                                          
  Pending                                     5 (3.9)                                          
  Unknown                                     1 (0)                                            
  Initial pre-authorization decision, n (%)   Approval                                         100 (77.5)
  Denial or pending                           24 (18.6)                                        
                                              Time to decision in days, mean ± SD, (n)         26.1 ± 25.2 (126)
                                              Time to approval in days, mean ± SD, (n)         22.9 ± 21.2 (117)
                                              Time to denial in days, mean ± SD, (n)           32.8 ± 20.2 (4)
                                              Appeal required, n (%)                           19 (14.7)
  Result of appeal, n (%)                     Approval                                         17 (89.5)
  Denial                                      1 (5.3)                                          
  Approval                                    1 (5.3)                                          
                                              Time of appeal process in days, mean ± SD, (n)   18.6 ± 22.1 (18)

[Table 5](#pone.0135645.t005){ref-type="table"} summarizes the time-to-decision in all subjects with outcomes data and time-to-approval in those who were approved for pre-authorization. Females were found to have a significantly lower time-to-decision than males (19.8 vs. 30.0 days, p = 0.01) with a similar but non-significant finding in time-to-approval. Those with a Medicare/Medicaid had a shorter average time-to-decision and time-to-approval though this finding was not significant (22.6 vs. 28.7 days, p = 0.18 & 19.2 vs. 25.9 days, p = 0.08, respectively). Those with Child-Pugh class B cirrhosis had a significantly shorter approval time (14.4 vs. 24.7 days, p = 0.048). Similar, non-significant findings were noted with those with advanced fibrosis and decompensated cirrhosis. Pre-authorization requests from liver transplant clinic were found to have a faster average time-to-decision and time-to-approval than pre-authorization requests from other clinics (17.9 vs. 28.9 days, p = 0.03 & 14.8 vs. 25.6 days, p = 0.02, respectively).

10.1371/journal.pone.0135645.t005

###### Time-to-decision and time-to-approval in patients receiving SOF/LED therapy.
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  Characteristic              Time to Decision   Time to Approval                                                     
  --------------------------- ------------------ ------------------ ------------- ------- ------------- ------------- -------
  Age in years                ≥60                71                 29.7 ± 29.2   0.055   53            20.2 ± 16.6   0.187
  \<60                        55                 21.4 ± 18.2        0.055         64      25.2 ± 24.3   0.187         
  Gender                      Male               77                 30.0 ± 28.7   0.01    69            25.3 ± 23.6   0.128
  Female                      49                 19.8 ± 16.9        0.01          48      19.6 ± 16.9   0.128         
  Race                        White              86                 26.6 ± 26.8   0.72    79            22.2 ± 20.8   0.57
  Other                       40                 24.9 ± 21.8        0.72          38      24.6 ± 22.3   0.57          
  Black                       24                 26.8 ± 22.4        0.88          23      26.7 ± 22.9   0.35          
  Other                       102                25.9 ± 25.9        0.88          94      22.0 ± 20.8   0.35          
  Hispanic                    21                 26.0 ± 22.6        0.99          20      25.7 ± 23.1   0.53          
  Other                       105                26.1 ± 25.8        0.99          97      22.4 ± 20.9   0.53          
  Insurance                   Private            63                 28.7 ± 24.0   0.18    55            25.9 ± 20.3   0.08
  Public                      63                 22.6 ± 25.2        0.18          60      19.2 ± 20.2   0.08          
  Cirrhosis                   Yes                77                 25.6 ± 23.3   0.81    72            22.9 ± 20.9   0.98
  No                          49                 26.7 ± 28.2        0.81          45      23.0 ± 21.9   0.98          
  Advanced Fibrosis           Yes                87                 23.2 ± 22.6   0.08    82            20.6 ± 20.1   0.07
  No                          39                 32.5 ± 29.6        0.08          35      28.4 ± 23.2   0.07          
  Prior HCV Treatment         Yes                56                 27.4 ± 26.7   0.60    49            21.7 ± 21.3   0.60
  No                          70                 25.0 ± 24.1        0.60          68      23.8 ± 21.3   0.60          
  Multiple prior treatments   Yes                22                 31.4 ± 28.6   0.28    19            27.3 ± 27.4   0.33
  No                          104                25.0 ± 24.4        0.28          98      22.1 ± 19.9   0.33          
  Decompensated cirrhosis     Yes                26                 19.5 ± 22.8   0.14    25            17.1 ± 19.6   0.12
  No                          100                27.8 ± 25.6        0.14          92      24.5 ± 21.5   0.12          
  Viral load                  ≥6M                16                 33.6 ± 35.7   0.36    14            27.6 ± 29.0   0.52
  \<6M                        110                25.0 ± 23.3        0.36          103     22.3 ± 20.1   0.52          
  Transplant clinic           Yes                32                 17.9 ± 20.6   0.03    29            14.8 ± 17.7   0.02
  No                          94                 28.9 ± 26.1        0.03          88      25.6 ± 21.7   0.02          
  GFR                         \>60               112                26.5 ± 24.9   0.58    104           23.5 ± 20.9   0.39
  ≤60                         14                 22.6 ± 28.5        0.58          13      18.2 ± 24.2   0.39          
  Child-Pugh class            A                  105                27.8 ± 25.2   0.09    97            24.7 ± 21.1   0.048
  B                           21                 17.5 ± 24.2        0.09          20      14.4 ± 20.1   0.048         
  HIV co-infection            Yes                3                  11.0 ± 5.3    0.30    3             11.0 ± 5.3    0.33
  No                          123                26.4 ± 25.4        0.30          114     23.3 ± 21.4   0.33          

[Table 6](#pone.0135645.t006){ref-type="table"} summarizes proportions of unapproved and initially approved for those whom pre-authorization was sent categorized by patient characteristics. A significantly higher proportion of patients with Medicare/Medicaid were initially approved compared to those with private insurance (92.2% vs. 71.4%, p = 0.002). In addition, a significantly higher proportion of patients with a viral load ≥6 million were initially approved compared to individuals with viral load \< 6 million (84.1% vs. 62.5%, p = 0.04).

10.1371/journal.pone.0135645.t006

###### Disapproval and initial-approval rates in patients receiving SOF/LED preauthorization request.
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  Characteristic              Unapproved, n (%)   Initially Approved, n (%)   Chi-square   P-value   
  --------------------------- ------------------- --------------------------- ------------ --------- -------
  Age                         ≥60 years           61 (58.1)                   44 (41.9)    1.19      0.28
  \<60 years                  11 (45.8)           13 (54.2)                   1.19         0.28      
  Gender                      Male                17 (21.5)                   62 (78.5)    1.14      0.29
  Female                      7 (14)              43 (86)                     1.14         0.29      
  Race                        White               19 (21.6)                   69 (78.4)    N/A       0.09
  Other                       5 (12.2)            36 (87.8)                   N/A          0.09      
  Black                       4 (16.0)            21 (84.0)                   N/A          0.22      
  Other                       20 (19.2)           84 (80.8)                   N/A          0.22      
  Hispanic                    4 (19.1)            17 (81.0)                   N/A          0.24      
  Other                       20 (18.5)           88 (81.5)                   N/A          0.24      
  Insurance                   Private             18 (28.6)                   45 (71.4)    N/A       0.002
  Public                      5 (7.8)             59 (92.2)                   N/A          0.002     
  Cirrhosis                   Yes                 13 (16.7)                   65 (83.3)    0.49      0.48
  No                          11 (21.6)           40 (78.4)                   0.49         0.48      
  Advanced Fibrosis           Yes                 14 (15.7)                   75 (84.3)    1.57      0.21
  No                          10 (25.0)           30 (75.0)                   1.57         0.21      
  Prior HCV Treatment         Yes                 14 (24.6)                   43 (75.4)    2.39      0.122
  No                          10 (13.9)           62 (86.1)                   2.39         0.122     
  Multiple prior treatments   Yes                 7 (31.8)                    15 (68.2)    3.06      0.08
  No                          17 (15.9)           90 (84.1)                   3.06         0.08      
  Decompensated cirrhosis     Yes                 2 (7.7)                     24 (92.3)    N/A       0.07
  No                          22 (21.4)           81 (78.6)                   N/A          0.07      
  Viral load                  ≥6M                 6 (37.5)                    10 (62.5)    4.31      0.04
  \<6M                        18 (15.9)           95 (84.1)                   4.31         0.04      
  Transplant clinic           Yes                 6 (17.7)                    28 (82.4)    0.03      0.867
  No                          18 (19.0)           77 (81.1)                   0.03         0.867     
  Renal function              GFR \>60            22 (19.1)                   93 (80.9)    N/A       0.276
  GFR ≤60                     2 (14.3)            12 (85.7)                   N/A          0.276     
  Child-Pugh class            A                   21 (19.4)                   87 (80.6)    N/A       0.221
  B                           3 (14.3)            18 (85.7)                   N/A          0.221     
  HIV co-infection            Yes                 0 (0)                       3 (100)      N/A       0.40
  No                          23 (19.1)           102 (81.0)                  N/A          0.40      

Univariate linear regression modeling results are shown in [Table 7](#pone.0135645.t007){ref-type="table"}. Significant associations to shorter times-to-decision and times-to-approval were noted with psychiatric disease, high FIB-4 score, and pre-authorization request from transplant clinic. Also, significantly shorter times were noted with increases in total bilirubin, INR, FIB-4 score, and MELD score. [Table 8](#pone.0135645.t008){ref-type="table"} summarizes univariate logistic regression model results. This analysis revealed that having Medicare/Medicaid (OR 4.72, 95% CI 1.63--13.67) and a high viral load (OR 3.17, 1.02--9.81) were associated with higher odds of initial approval compared to private insurance and low viremia, respectively.

10.1371/journal.pone.0135645.t007

###### Univariate linear regression analysis with time-to-decision and time-to-approval.
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                                  Variable            Time-to-Decision (n = 126)   Time-to-Approval (n = 117)           
  ------------------------------- ------------------- ---------------------------- ---------------------------- ------- -------
  Continuous Variables            Age                 -0.35                        0.117                        -0.19   0.348
  AST                             -0.01               0.848                        -0.06                        0.186   
  ALT                             -0.08               0.143                        0.02                         0.698   
  Alkaline phosphatase            -0.004              0.922                        0.001                        0.976   
  Total bilirubin                 -8.71               0.036                        -7.55                        0.032   
  Creatinine                      2.61                0.740                        0.11                         0.987   
  Platelets                       0.03                0.291                        0.05                         0.055   
  INR                             -38.62              0.022                        -37.78                       0.028   
  FIB-4 score                     -0.93               0.031                        -0.89                        0.014   
  MELD                            -2.39               0.013                        -2.10                        0.011   
  Viral load in millions          0.41                0.445                        0.46                         0.311   
  Log~10~(viral load)             4.81                0.076                        4.76                         0.040   
  Dichotomous Variables           Private insurance   6.02                         0.176                        6.65    0.081
  Hypertension                    -0.64               0.888                        5.11                         0.196   
  Psychiatric disease             -3.60               0.435                        -8.84                        0.028   
  Antecedent HCV treatment        2.38                0.601                        -2.09                        0.602   
  Multiple prior HCV treatments   6.41                0.281                        5.21                         0.330   
  High FIB-4 (\>3.25) score       -6.89               0.140                        -10.03                       0.013   
  Any cirrhosis                   -1.09               0.815                        -0.08                        0.984   
  Decompensated cirrhosis         -8.28               0.137                        -7.46                        0.120   
  Transplant clinic               -10.99              0.033                        -10.80                       0.017   

10.1371/journal.pone.0135645.t008

###### Univariate logistic regression analysis for initial approval.
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  Variable                        Odds ratio (95% CI)   p-value
  ------------------------------- --------------------- ---------
  Age ≥ 60 (vs. \<60yo)           1.64 (0.67--4.00)     0.278
  Public insurance                4.72 (1.63--13.67)    0.004
  Hypertension                    1.94 (0.79--4.77)     0.148
  Psychiatric disease             0.35 (0.12--1.01)     0.052
  Antecedent HCV treatment        2.02 (0.82--4.96)     0.126
  Multiple prior HCV treatments   2.47 (0.88--6.96)     0.087
  High FIB-4 (\>3.25) score       0.67 (0.26--1.76)     0.414
  Advanced fibrosis (F3-4)        0.56 (0.22--1.40)     0.214
  Any cirrhosis (F4)              0.72 (0.30--1.78)     0.485
  Decompensated cirrhosis         0.30 (0.07--1.40)     0.127
  Transplant clinic               0.92 (0.33--2.54)     0.867
  Viral load ≥6 M (vs. \<6 M)     3.17 (1.02--9.81)     0.046
  White race                      1.98 (0.68--5.75)     0.208
  Black race                      0.80 (0.25--2.59)     0.710
  Hispanic ethnicity              1.04 (0.31--3.41)     0.954
  GFR \< 60 (vs. GFR ≥60)         1.41 (0.30--6.80)     0.662

Multivariate linear and logistic models are shown in Tables [9](#pone.0135645.t009){ref-type="table"}--[16](#pone.0135645.t016){ref-type="table"}. In multivariate linear models, forward stepwise addition revealed that MELD score, female gender, and advanced fibrosis were significant predictors of a shorter time-to-decision and time-to-approval, while psychiatric disease was found to be a significant predictor of a shorter time-to-approval. These associations were persistent after controlling for age and race (Tables [12](#pone.0135645.t012){ref-type="table"}--[14](#pone.0135645.t014){ref-type="table"}). Forward stepwise selection logistic regression modeling revealed that having Medicare/Medicaid (OR 5.96, 95% CI 1.66--21.48) and viral load ≥6 million IU/mL (OR 4.54, 95% CI 1.08--19.08) were significant predictors of initial approval and persisted after controlling for age, gender, race, presence of cirrhosis or hypertension, and pre-authorization request from transplant clinic (Tables [15](#pone.0135645.t015){ref-type="table"} and [16](#pone.0135645.t016){ref-type="table"}).

10.1371/journal.pone.0135645.t009

###### Multivariate analyses for [time-to-decision]{.ul} (n = 123).

Stepwise linear regression model for time-to-decision.

![](pone.0135645.t009){#pone.0135645.t009g}

  Variable            Parameter Estimate   Partial R^2^   F-statistic   P-value
  ------------------- -------------------- -------------- ------------- ---------
  MELD score          -2.41                0.057          7.32          0.0078
  Male Gender         13.08                0.051          6.86          0.0099
  Advanced Fibrosis   -9.61                0.029          4.06          0.0462

Total model R^2^ = 0.137, F-value = 6.32, p = 0.0005

10.1371/journal.pone.0135645.t010

###### Multivariate analyses for [time-to-decision]{.ul} (n = 123).

Prediction of [time-to-decision]{.ul} based on linear multivariate model with selected variables (from stepwise selection as above) and demographic covariates (n = 123).
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  Variable            Parameter Estimate (SE)   t-value   p-value
  ------------------- ------------------------- --------- ---------
  Advanced Fibrosis   -11.17 (4.9)              -2.27     0.025
  Male gender         11.38 (4.67)              2.42      0.017
  Age (≥60 years)     -6.51 (4.52)              -1.44     0.152
  White race          4.08 (7.65)               0.53      0.595
  Black race          4.95 (9.04)               0.55      0.585
  Hispanic            0.99 (6.78)               0.15      0.884

Model R^2^ = 0.104, F-value = 2.29, p = 0.040

10.1371/journal.pone.0135645.t011

###### Multivariate analyses for [time-to-decision]{.ul} (n = 123).

Prediction of [time-to-decision]{.ul} based on linear multivariate model with selected variables (from stepwise selection as above) and demographic covariates (n = 123).
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  Variable          Parameter Estimate (SE)   t-value   p-value
  ----------------- ------------------------- --------- ---------
  MELD score        -2.72 (0.97)              -2.80     0.006
  Male gender       11.25 (4.60)              2.45      0.016
  Age (≥60 years)   -5.84 (4.49)              -1.30     0.196
  White race        6.70 (8.56)               0.89      0.377
  Black race        5.80 (8.94)               0.65      0.518
  Hispanic          6.36 (6.73)               0.94      0.347

Model R^2^ = 0.154, F-value = 4.99, p = 0.0010

10.1371/journal.pone.0135645.t012

###### Multivariate model for [time-to-approval]{.ul} (n = 117).

Models included in final model after stepwise linear regression modeling.
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  Variable                    Parameter Estimate   Partial R^2^   F-statistic   P-value
  --------------------------- -------------------- -------------- ------------- ---------
  MELD score                  -2.17                0.068          8.30          0.0047
  Prior psychiatric disease   -8.17                0.039          4.92          0.0286
  Gender (1 = male)           7.68                 0.023          2.97          0.0877
  Advanced fibrosis           7.83                 0.028          3.64          0.0591

Total model R^2^ = 0.159, F-value = 5.19, p = 0.0007

10.1371/journal.pone.0135645.t013

###### Multivariate model for [time-to-approval]{.ul} (n = 117).

Prediction of [time-to-approval]{.ul} based on linear multivariate model with selected variables (from stepwise selection as above) and demographic covariates (n = 117).
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  Variable                    Parameter Estimate (SE)   t-value   p-value
  --------------------------- ------------------------- --------- ---------
  MELD score                  -2.38 (0.84)              -2.83     0.0014
  Prior psychiatric disease   -8.67 (3.93)              -2.20     0.0298
  Gender (1 = male)           7.10 (3.92)               1.81      0.0723

Model R^2^ = 0.147, F-value = 2.67, p = 0.0136

Model in this table was controlled for: age, gender, race

10.1371/journal.pone.0135645.t014

###### Multivariate model for [time-to-approval]{.ul} (n = 117).

Prediction of [time-to-approval]{.ul} based on linear multivariate model with selected variables (from stepwise selection as above) and demographic covariates (n = 117).
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  Variable                    Parameter Estimate (SE)   t-value   p-value
  --------------------------- ------------------------- --------- ---------
  Advanced Fibrosis           -8.91 (4.42)              -2.02     0.0461
  Prior psychiatric disease   -9.28 (4.00)              -2.32     0.0222
  Gender (1 = male)           6.92 (4.02)               1.72      0.0879

Model R^2^ = 0.117, F-value = 2.06, p = 0.054

Model in this table was controlled for: age, gender, race

10.1371/journal.pone.0135645.t015

###### Multivariate Logistic Modeling for [proportion initially approved]{.ul}, (n = 123).

Models included in final model after stepwise logistic regression modeling.
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  Variable             Chi-Square   p-value
  -------------------- ------------ ---------
  Insurance provider   9.23         0.0024
  Viral load (≥6M)     4.95         0.0262
  Hypertension         3.19         0.0739

Included covariates: age, gender, race (3x binary variables: white vs. other, black vs. other, Hispanic vs. non-hispanic), insurance (private vs. public), transplant clinic, viral load (≥6M vs. \<6M), body mass index, multiple antecedent HCV treatments, meld score, hypertension, diabetes, psychiatric conditions, cirrhosis, advanced fibrosis, FIB-4 score, total bilirubin, INR, creatinine

10.1371/journal.pone.0135645.t016

###### Multivariate Logistic Modeling for [proportion initially approved]{.ul}, (n = 123).

Logistic model with selected variables, including other clinically-relevant covariates, in predicting [initial approval]{.ul} (n = 123).
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  Variable                                  Odds ratio (95% CI)   Chi-Square   p-value
  ----------------------------------------- --------------------- ------------ ---------
  Medicare or Medicaid Insurance provider   5.96 (1.66--21.48)    7.46         0.0063
  Viral load (≥6M)                          4.54 (1.08--19.08)    4.27         0.0388

Model controlled for age, gender, race, hypertension, presence of cirrhosis, transplant clinic (measures of covariate associations not listed).

Discussion {#sec013}
==========

In our cohort of patients receiving pre-authorization request for SOF/LED over a three-month period, we found that nearly one in four were denied initial approval, although most patients eventually obtained drug authorization through the appeals process. Female gender, advanced Child-Pugh class, and liver transplant clinic were associated with shorter decision or approval times. Finally, having Medicare/Medicaid and a high viral load were significant predictors for initial approval, with findings persisting after controlling for demographic covariates.

The cascade of care model for HCV treatment involves numerous steps from diagnosis to successful treatment and viral eradication with patient drop-out observed at every step \[[@pone.0135645.ref011]\]. This analysis focused on one specific process: pre-authorization request and approval in those with a known diagnosis of HCV infection prescribed SOF/LED. Fewer than 10% patients ultimately failed to obtain access to therapy, although the appeals process led to further delay to treatment initiation. Importantly, the proportion of patients with access to drug therapy may be overestimated as this analysis was largely restricted to insured patients, all of whom had already successfully linked to specialty care in a major tertiary care university liver clinic, completed a series of pre-treatment evaluations and a formal structured HCV class, and were deemed by a specialty provider to represent an appropriate candidate with adequate motivation to initiate treatment.

The higher approval rates in patients with Medicare/Medicaid was unexpected, and could not be explained by other patient or medical variables, as this association remained significant in the multivariate model. Following Food and Drug Administration (FDA) approval of SOF/LED on October 10, 2014, updates to AASLD-IDSA HCV treatment recommendations affirmed that treatment be considered for all patients regardless of disease severity, although with the highest priority given to patients with advanced fibrosis, transplant recipients, or those with severe renal insufficiency \[[@pone.0135645.ref003]\]. Our hypothesis is that the higher than expected authorization rates by Medicare/Medicaid represented a time-limited anomaly driven by the absence of prior authorization guidelines until December 2014 and January 2015, through which Harvoni has been restricted by state Medicaid to patients with advanced liver fibrosis or cirrhosis (F3/F4), and selected patients at high risk for disease progression, and must be prescribed by specialty physicians \[[@pone.0135645.ref026], [@pone.0135645.ref027]\]. Restrictive prior authorization guidelines were established by many public and private payors in this state by early 2015 ([Table 17](#pone.0135645.t017){ref-type="table"}). As nearly half of patients prescribed SOF/LED in this analysis had Medicare/Medicaid coverage, drug authorization rates would be expected to be lower beyond January 2015.

10.1371/journal.pone.0135645.t017

###### Select information requested for pre-authorization for specified insurance providers.

Exact criteria should be found in appropriate insurance pre-authorization form.
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                       HCV Genotype/Subtype   Viral Load   Presence of advanced fibrosis or cirrhosis   Presence of hepatic decompensation   Mechanism of fibrosis staging and result   Liver transplant recipient   Non liver transplant recipient   Presence of ESRD   Cryoglobulinemia or glomerular disease   HIV co-infection +/- viral load count   HBV co-infection   Prior sofosbuvir treatment and response   Other prior HCV treatment & response   Drug/alcohol use   Prescriber specific criteria
  -------------------- ---------------------- ------------ -------------------------------------------- ------------------------------------ ------------------------------------------ ---------------------------- -------------------------------- ------------------ ---------------------------------------- --------------------------------------- ------------------ ----------------------------------------- -------------------------------------- ------------------ ------------------------------
  Accredo              x                      x                                                                                                                                                                                                                                                                                                                                                                        x                                                         
  Aetna/Open Choice    x                      x            x                                            x                                    x                                          x                            x                                x                                                           x                                       x                                                            x                                                         
  Anthem               x                      x            x                                            x                                    x                                          x                                                             x                  x                                                                                                   x                                         x                                      x                  
  AARP                 x                      x            x                                            x                                    x                                                                                                                                                                                                                                                                         x                                                         x
  Catamaran            x                                   x                                                                                                                                                                                          x                                                                                                                      x                                                                                                   x
  Cigna                x                      x            x                                                                                 x                                                                                                                                                                                                                                                                         x                                      x                  x
  Connecticare         x                      x            x                                                                                                                                                                                                                                                                                                                                                           x                                                         
  CVS Caremark         x                      x                                                                                                                                                                                                                                                                                                                              x                                         x                                                         x
  Medicare             x                      x            x                                            x                                                                               x                                                                                                                                                                                                                                                                                        x
  Medicaid             x                      x            x                                                                                 x                                                                                                        x                                                           x                                                          x                                                                                                   x
  Oxford               x                                                                                x                                    x                                          x                                                             x                                                           x                                                                                                    x                                      x                  x
  Tricare              x                      x            x                                                                                                                                                                                                                                                                                              x                  x                                         x                                                         x
  United Health Care   x                                                                                x                                    x                                          x                                                             x                                                           x                                                                                                    x                                      x                  x

In our cohort, patients in the liver transplant clinic were found to have shorter approval times, which may be attributable in part to overrepresentation of advanced liver disease in this population, and therefore likely be given initial approval through the pre authorization process with both public and private payors. We could not exclude the potential effect of variable access to certified specialty pharmacies with capacity to directly dispense SOF/LED medications to patients.

This is the first study to our knowledge assessing real-world access to interferon-free DAA regimens in established cohorts of patients with chronic HCV seeking antiviral therapy. These results contribute to the limited data available addressing proportion of patients successfully obtaining drug authorization through public and private insurance carriers, time to approval, and predictors for approval. Several limitations of our study warrant further investigation. We did not record data on proportion of treatment-eligible patients seeking treatment who declined to pursue SOF/LED prescription due to absence of insurance coverage, or perception of difficulty in accessing treatment due to mild liver fibrosis or other factors. Although the analysis was performed for consecutive unselected patients prescribed SOF/LED, this cohort represented a subset of patients who were deemed to be excellent candidates for treatment, and therefore selection bias by prescribing providers for individuals with anticipated approval could not be excluded. This study is also limited to authorization data in Connecticut, and state Medicaid and Medicare approval rates likely differ by states as well. Furthermore this study is focused exclusively on SOF/LED, and authorization results may be different for other FDA-approved interferon-free regimens such as sofosbuvir/simeprevir and paritaprevir/ritonavir, ombitasvir, dasabuvir, and ribavirin. Future studies are needed to clarify the variance in public and private insurance access to HCV regimens across states, stratified by liver fibrosis and other patient characteristics, the outcome of appeal requests, and approval of requests which are beyond FDA label or AASLD/IDSA recommendations.

In conclusion, we found that most patients filing a pre-authorization request for SOF/LED are eventually approved, but nearly 1 in 4 were denied access upon initial request, which may represent a barrier within the HCV care cascade. On multivariate analysis, advanced liver disease was associated with faster approval time, while Medicare/Medicaid and high viremia were associated with insurance approval. Further studies are warranted to investigate the impact of evolving drug authorization policies by Medicare/Medicaid and private payers on access to curative HCV therapies such as SOF/LED.

Supporting Information {#sec014}
======================

###### Full dataset with SAS code.

(SAS)

###### 

Click here for additional data file.
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